MX2020001201A - Anticuerpos anti-activina a y usos de los mismos. - Google Patents

Anticuerpos anti-activina a y usos de los mismos.

Info

Publication number
MX2020001201A
MX2020001201A MX2020001201A MX2020001201A MX2020001201A MX 2020001201 A MX2020001201 A MX 2020001201A MX 2020001201 A MX2020001201 A MX 2020001201A MX 2020001201 A MX2020001201 A MX 2020001201A MX 2020001201 A MX2020001201 A MX 2020001201A
Authority
MX
Mexico
Prior art keywords
antibodies
activin
useful
treatment
diseases
Prior art date
Application number
MX2020001201A
Other languages
English (en)
Inventor
C Morton Lori
Gromada Jesper
D Yancopoulos George
Latres Esther
J Murphy Andrew
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020001201A publication Critical patent/MX2020001201A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención provee anticuerpos que se unen a Activina A y métodos para el uso de los mismos. Los anticuerpos son totalmente humanos y se unen a Activina A con elevada afinidad. Estos anticuerpos son útiles para el tratamiento de enfermedades y trastornos caracterizados por fuerza o masa muscular reducida, tal como sarcopenia, caquexia, lesión muscular, cáncer, fibrosis y pérdida de peso. Los anticuerpos de la invención también son útiles en combinación con proteínas de unión a GDF8 para el tratamiento de enfermedades y trastornos caracterizados por fuerza o masa muscular reducida. Los anticuerpos de la invención son también útiles para la prevención, tratamiento o alivio de trastornos y enfermedades causadas por, promovidas por, exacerbadas por y/o agravadas por Activina A, como la fibrosis renal.
MX2020001201A 2013-07-30 2014-07-30 Anticuerpos anti-activina a y usos de los mismos. MX2020001201A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361859926P 2013-07-30 2013-07-30
US201361864036P 2013-08-09 2013-08-09
US201361911834P 2013-12-04 2013-12-04
US201361913885P 2013-12-09 2013-12-09
PCT/US2014/048957 WO2015017576A1 (en) 2013-07-30 2014-07-30 Anti-activin a antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2020001201A true MX2020001201A (es) 2021-01-28

Family

ID=52427866

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001394A MX371498B (es) 2013-07-30 2014-07-30 Anticuerpos anti-activina a y usos de los mismos.
MX2020001201A MX2020001201A (es) 2013-07-30 2014-07-30 Anticuerpos anti-activina a y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016001394A MX371498B (es) 2013-07-30 2014-07-30 Anticuerpos anti-activina a y usos de los mismos.

Country Status (28)

Country Link
US (4) US9718881B2 (es)
EP (4) EP3730151A1 (es)
JP (5) JP6581085B2 (es)
KR (2) KR102315694B1 (es)
CN (2) CN105592858B (es)
AU (2) AU2014296243B2 (es)
BR (1) BR112016002164B1 (es)
CA (1) CA2920071C (es)
CL (1) CL2016000251A1 (es)
CY (1) CY1123788T1 (es)
DK (1) DK3027209T3 (es)
EA (1) EA037926B1 (es)
ES (1) ES2827673T3 (es)
HK (1) HK1225322A1 (es)
HR (1) HRP20201729T1 (es)
HU (1) HUE052518T2 (es)
IL (2) IL243822B (es)
LT (1) LT3027209T (es)
MX (2) MX371498B (es)
PH (1) PH12016500182A1 (es)
PT (1) PT3027209T (es)
RS (1) RS61124B1 (es)
SG (1) SG11201600731WA (es)
SI (1) SI3027209T1 (es)
TW (2) TW201920262A (es)
UY (1) UY35682A (es)
WO (1) WO2015017576A1 (es)
ZA (1) ZA201601294B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI548647B (zh) 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2120999B1 (en) 2007-02-09 2012-08-29 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists and use thereof in preventing or treating multiple myeloma
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
PL2780368T3 (pl) 2011-11-14 2018-06-29 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EA039118B1 (ru) * 2015-04-01 2021-12-07 Ридженерон Фармасьютикалз, Инк. Способ лечения прогрессирующей оссифицирующей фибродисплазии
CA2982810A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
TW201713361A (zh) 2015-04-29 2017-04-16 Regeneron Pharma 進行性骨化性纖維發育不良之治療
TWI824372B (zh) * 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20180008672A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
EP3522934A4 (en) * 2016-10-05 2020-04-15 Acceleron Pharma Inc. COMPOSITIONS AND METHOD FOR THE TREATMENT OF RENOPATHY
US20190240316A1 (en) * 2016-10-17 2019-08-08 Vanderbilt University Human respiratory syncytial virus antibodies and methods of use therefor
EP3538128A4 (en) * 2016-11-10 2020-07-22 Keros Therapeutics, Inc. ACTIVIN TYPE IIA RECEPTOR VARIANTS AND THEIR METHODS OF USE
DE102018103302A1 (de) * 2018-02-14 2019-08-14 Noonee Ag Tragbare Sitzhaltungshilfevorrichtung
CA3092334A1 (en) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
US11419319B2 (en) 2018-06-13 2022-08-23 Regeneran Pharmaceuticals, Inc. Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formation
WO2020131910A1 (en) 2018-12-18 2020-06-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a
CA3142149A1 (en) * 2019-05-30 2020-12-03 Acceleron Pharma, Inc. Actrii-binding proteins and uses thereof
CN115243763A (zh) 2020-01-08 2022-10-25 里珍纳龙药品有限公司 治疗进行性骨化性纤维发育不良
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2022009769A (es) 2020-02-11 2022-11-09 Regeneron Pharma Anticuerpos anti-acvr1 y usos de los mismos.
CA3183316A1 (en) 2020-06-18 2021-12-23 Regeneron Pharmaceuticals, Inc. Activin a antibody formulations and methods of use thereof
KR20230051683A (ko) * 2020-08-20 2023-04-18 리제너론 파아마슈티컬스, 인크. 액티빈 a 길항제를 사용한 심장 기능 장애 및 covid-19의 예방 및 치료 방법
EP4387647A2 (en) * 2021-08-16 2024-06-26 Acceleron Pharma Inc. Compositions and methods for treating renal diseases or conditions
CA3235627A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2023154672A2 (en) * 2022-02-14 2023-08-17 Ohio University Methods for regulating muscle performance using fat specific protein 27 (fsp27) compositions
TWI819587B (zh) * 2022-04-29 2023-10-21 洪慧妤 用於預防癌症所引發的肌少症之組合物及組合物於製造供預防癌症所引發之肌少症食品的用途
US20240199728A1 (en) 2022-09-21 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
EP1333035A3 (en) 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
JP4544742B2 (ja) 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
EA005248B1 (ru) 1999-07-20 2004-12-30 Фармекса А/С Способ отрицательной регуляции активности gdf-8
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
AU2004245025A1 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
JP2007535912A (ja) 2003-12-31 2007-12-13 シェーリング−プラウ・リミテッド 中和エピトープベースの増殖増強性ワクチン
JP2007526337A (ja) 2004-03-02 2007-09-13 アクセルロン ファーマ インコーポレーテッド Ａｌｋ７およびミオスタチン阻害剤ならびにその使用
AU2005227896B2 (en) 2004-03-23 2008-11-13 Eli Lilly And Company Anti-myostatin antibodies
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
CA2575563A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US7807159B2 (en) 2005-04-25 2010-10-05 Amgen Fremont Inc. Antibodies to myostatin
WO2007024535A2 (en) 2005-08-19 2007-03-01 Wyeth Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
WO2007044411A2 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
UA98447C2 (ru) * 2005-11-23 2012-05-25 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА- ActRIIa И ИХ ПРИМЕНЕНИЕ ДЛЯ СОДЕЙСТВИЯ РОСТУ КОСТЕЙ
MX2008007324A (es) 2005-12-06 2009-03-04 Amgen Inc Usos de antagonistas de miostatina.
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
JP5058261B2 (ja) 2006-09-05 2012-10-24 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
MX2010004929A (es) 2007-11-05 2010-05-27 Novartis Ag Derivados de 4-bencil-amino-1-carboxi-acil-piperidina como inhibidores de proteina de transferencia de colesterol-ester (cetp) utiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis.
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
CA2997971A1 (en) * 2008-11-26 2010-06-03 Amgen Inc. Variants of activin iib receptor polypeptides and uses thereof
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
CA2758290C (en) 2009-04-27 2018-04-10 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
RU2522002C2 (ru) 2009-06-26 2014-07-10 Ридженерон Фармасьютикалз, Инк. Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
PL2780368T3 (pl) * 2011-11-14 2018-06-29 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
WO2013186719A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
JP2016508504A (ja) 2013-02-01 2016-03-22 サンタ マリア バイオセラピューティクス インコーポレイテッド 対象に対する抗アクチビン−ａ化合物の投与
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
CA2982810A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
CA3092334A1 (en) * 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition

Also Published As

Publication number Publication date
HUE052518T2 (hu) 2021-05-28
DK3027209T3 (da) 2020-11-02
BR112016002164B1 (pt) 2023-12-19
US9718881B2 (en) 2017-08-01
EP3027209A1 (en) 2016-06-08
PT3027209T (pt) 2020-10-22
WO2015017576A1 (en) 2015-02-05
JP2016528232A (ja) 2016-09-15
US10526403B2 (en) 2020-01-07
PH12016500182A1 (en) 2016-04-25
TW201602133A (zh) 2016-01-16
CA2920071A1 (en) 2015-02-05
EP4059520A1 (en) 2022-09-21
KR102315694B1 (ko) 2021-10-21
JP7496387B2 (ja) 2024-06-06
KR20160030581A (ko) 2016-03-18
NZ754959A (en) 2022-03-25
US20210163583A1 (en) 2021-06-03
IL270218B (en) 2021-01-31
LT3027209T (lt) 2020-12-28
IL243822B (en) 2019-11-28
HRP20201729T1 (hr) 2020-12-25
KR20210129253A (ko) 2021-10-27
JP2022130593A (ja) 2022-09-06
CY1123788T1 (el) 2022-03-24
EA201690243A1 (ru) 2016-06-30
ES2827673T3 (es) 2021-05-24
JP2021176887A (ja) 2021-11-11
RS61124B1 (sr) 2020-12-31
EP4062937A1 (en) 2022-09-28
CL2016000251A1 (es) 2017-07-14
AU2014296243B2 (en) 2019-11-21
JP2020011965A (ja) 2020-01-23
HK1225322A1 (zh) 2017-09-08
CN105592858A (zh) 2016-05-18
AU2014296243A1 (en) 2016-03-03
JP6923602B2 (ja) 2021-08-25
SG11201600731WA (en) 2016-02-26
MX2016001394A (es) 2016-08-03
AU2020200892A1 (en) 2020-03-05
JP6581085B2 (ja) 2019-09-25
ZA201601294B (en) 2017-05-31
MX371498B (es) 2020-01-31
KR102440044B1 (ko) 2022-09-06
SI3027209T1 (sl) 2020-11-30
CN113845594A (zh) 2021-12-28
JP7440464B2 (ja) 2024-02-28
US20180155416A1 (en) 2018-06-07
EP3730151A1 (en) 2020-10-28
BR112016002164A2 (pt) 2017-09-12
AU2020200892B2 (en) 2022-03-31
CA2920071C (en) 2023-05-23
CN105592858B (zh) 2021-10-01
US20230312699A1 (en) 2023-10-05
EA037926B1 (ru) 2021-06-08
TWI655207B (zh) 2019-04-01
IL243822A0 (en) 2016-04-21
UY35682A (es) 2015-02-27
JP2022160619A (ja) 2022-10-19
NZ716854A (en) 2022-03-25
US20150037339A1 (en) 2015-02-05
EP3027209B1 (en) 2020-09-02
TW201920262A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
PH12016500182A1 (en) Anti-activin a antibodies and uses thereof
HK1253065A1 (zh) 靶向蛋白質的化合物、其組合物、方法和用途
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
PH12016501644B1 (en) Binding proteins and methods of use thereof
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
SG11202111249YA (en) Virus compositions with enhanced specificity in the brain
PH12014501108A1 (en) Anti-il-36r antibodies
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
NZ707086A (en) Anti-cd40 antibodies and methods of use
PH12014502406A1 (en) Anti-il-23p19 antibodies
MX2015011075A (es) Peptidos terapeuticos.
MX2016004551A (es) Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
MX2013006875A (es) Anticuepos anti-notch1.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
IL237852A0 (en) Antibodies against amphigoline, medical preparations containing them and their use
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
WO2017019957A3 (en) Binding proteins and methods of use thereof
EP3288542A4 (en) Compositions and methods for administering antibodies
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MY186726A (en) Anti-activin a antibodies and uses thereof
EA202091757A3 (ru) Антитела к активину а и их применение
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations